Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jay R. LulyPresident and CEO | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 4,743 sh | $14.23 | $67,492.89 | −0.5% |
Yat Sun OrChief Scientific Officer | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 2,390 sh | $14.23 | $34,009.7 | −0.6% |
Tara Lynn KiefferChief Product Strategy Officer | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 2,106 sh | $14.23 | $29,968.38 | −6.4% |
Brendan LuuChief Business Officer | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 1,394 sh | $14.23 | $19,836.62 | −3.5% |
Scott T. RottinghausChief Medical Officer | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 798 sh | $14.23 | $11,355.54 | −3.5% |
Harry R. Trout IIISEE REMARKS | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 542 sh | $14.23 | $7,712.66 | −3.2% |
Kathleen S. CappsSEE REMARKS | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/05 | 25/12/05 | 323 sh | $14.23 | $4,596.29 | −3.7% |
Harry R. Trout IIISEE REMARKS | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/02 | 25/12/03 | 380 sh | $13.96 | $5,304.8 | −2.2% |
Kathleen S. CappsSEE REMARKS | Enanta PharmaceuticalsENTA | Open-market sale | 25/12/02 | 25/12/03 | 207 sh | $13.96 | $2,889.72 | −2.3% |
Jay R. LulyPresident and CEO | Enanta PharmaceuticalsENTA | Open-market buy | 25/02/12 | 25/02/12 | 45,000 sh | $5.69 | $256,050 | +5.6% |
Paul J. MellettChief Fin. & Admin Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 2,591 sh | $8.06 | $20,883.46 | −2.7% |
Jay R. LulyPresident and CEO | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 5,142 sh | $8.06 | $41,444.52 | −0.6% |
Yat Sun OrChief Scientific Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 2,591 sh | $8.06 | $20,883.46 | −0.7% |
Tara Lynn KiefferChief Product Strategy Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 2,283 sh | $8.06 | $18,400.98 | −7.2% |
Brendan LuuChief Business Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 2,283 sh | $8.06 | $18,400.98 | −6.0% |
Scott T. RottinghausChief Medical Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/12/06 | 24/12/10 | 866 sh | $8.06 | $6,979.96 | −4.6% |
Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/07/11–24/07/15 | 24/07/15 | 11,945 sh3 trades | $15.97avg. | $190,746.77 | −35.5% | |
Tara Lynn KiefferChief Product Strategy Officer | Enanta PharmaceuticalsENTA | Open-market sale10b5-1 plan | 24/06/17 | 24/06/17 | 7,266 sh | $12.33 | $89,589.78 | −18.3% |
Terry VanceDirector | Enanta PharmaceuticalsENTA | Open-market sale | 23/12/13 | 23/12/15 | 15,295 sh | $9.12 | $139,490.4 | −72.5% |
Paul J. MellettSr. VP, Finance & Admin. & CFO | Enanta PharmaceuticalsENTA | Open-market sale | 23/12/05 | 23/12/06 | 2,412 sh | $9.63 | $23,227.56 | −2.5% |